Modulation of Condensate Regulatory Processes for Drug Discovery

CD BioSciences offers a variety of condensate-based drug discovery strategies to achieve repair condensatopathy, disrupt the normal function of condensates associated with disease, and prevent targets from acting by disabling them in their natural condensates or by separating them from their natural condensates. Here, we help you with drug development by modulating condensate regulatory processes.

Introduction of Condensate Regulatory Processes

Many regulators of chromatin, transcription, and RNA processing form biomacromolecular condensates typically via liquid-liquid phase separation (LLPS). Thus, biomacromolecular condensates regulate various cellular functions such as signal transduction, stress adaptation, and gene regulation. The physicochemical properties and functions of condensates are determined by the structural and conformational characteristics of their components and the extended molecular network between them; thus, changes in environmental conditions, gene modifications, post-translational modifications (PTMs), and other processes that alter this balance regulate agglutinates. Abnormal perturbations of any of these parameters lead to a pathogenic state of the cell, and the same pathogenic endpoint can be achieved by other mechanisms regulating the regulatory processes of the condensate.

Fig. 1. Protein condensates that regulate different steps of gene expression in the nucleus. (Li W, et al, 2022)

Our Solutions

CD BioSciences is committed to developing cutting-edge solutions for regulating condensate regulatory processes to drive drug discovery. Our multidisciplinary team of biologists, biochemists, and computational scientists collaborate to design innovative approaches that target specific condensates involved in disease pathology.

Our solutions span a range of approaches, including:

• Enzyme-targeted Therapies
  We use rational drug design and high-throughput screening methods to identify enzymes that selectively target those involved in condensation regulation. By modulating the activity or expression of these enzymes, we aim to alter biomolecular conformation, solubility, valence, or turnover kinetics, leading to their separation from condensates, or to modulate condensate composition and function.
• PTM-based Interventions
  With our expertise in post-translational modifications, we explore the role of PTM in condensate biology. Through comprehensive PTM analysis, we can identify modifications that critically affect condensate behavior. Furthermore, by designing molecules that selectively modulate these PTMs, we aim to restore normal condensate function and alleviate disease-related dysfunction.
• DNA- or RNA-based Interventions
  We can alter the ability of a biomolecule to nucleate to form a condensate, alter its residence time in the condensate or alter the function of that biomolecule within the condensate by altering the epigenetic or epigenetic transcriptional state of the DNA or RNA.

Based on enzyme-targeted therapies, altered PTM, DNA or RNA epigenetic or epigenetic transcriptional states, CD BioSciences aims to provide new possibilities for the development of therapies that selectively target condensate dysregulation, opening up avenues for the treatment of various diseases. If you are interested in our solutions, please contact us now to seize new drug development opportunities.